VIA
RCKT icon

Virtus Investment Advisers’s Rocket Pharmaceuticals RCKT Stock Holding History

Virtus Investment Advisers’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$407K Buy
118,981
+38,543
+48% +$128K 0.09% 271
2026
Q1 		$288K Buy
80,438
+1,964
+3% +$7.81K 0.08% 286
2025
Q4 		$275K Buy
78,474
+41,410
+112% +$142K 0.07% 279
2025
Q3 		$121K Buy
37,064
+6,434
+21% +$20.3K 0.03% 404
2025
Q2 		$75K Buy
30,630
+17,572
+135% +$89K 0.03% 434
2025
Q1 		$87.1K Buy
+13,058
New +$129K 0.02% 440

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Virtus Investment Advisers's RCKT Position: Q2 2026 in Review

Virtus Investment Advisers increased its Rocket Pharmaceuticals (RCKT) stake by 48% in Q2 2026, buying an estimated $128K and bringing the position to 118,981 shares worth $407K. The position accounts for 0.09% of the portfolio, ranked #271.

Virtus Investment Advisers first reported a position in RCKT in Q1 2025 and has held it in 6 quarters since. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Virtus Investment Advisers held 118,981 shares of Rocket Pharmaceuticals worth $407K as of Q2 2026.
  • Virtus Investment Advisers bought 38,543 Rocket Pharmaceuticals shares in Q2 2026, an estimated $128K.
  • Rocket Pharmaceuticals made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #271 holding.
  • Virtus Investment Advisers first reported a position in Rocket Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.